Entheon Biomedical Corp.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception. We are committed to the legal development of regulated, safe & effective, psychedelic therapies, and in demonstrating their efficacy when administered in a scientifically-validated manner.

Recent News

  • Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

    Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances ("DMT") for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the...

    2020-12-09 8:30 AM ET
  • Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

    Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific").Wonder Scientific's team of University Researchers and Product Development experts create custom, naturally derived, active pharmaceutical ingredients (APIs) to supply the growing global clinical and commercial demand for psychedelics. Entheon's first strategic investment provides exposure in other verticals of the...

    2020-12-04 8:30 AM ET
  • Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

    Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre for Human Drug Research (CHDR) to conduct an early phase human clinical trial with DMT. CHDR is a Leiden, Netherlands-based contract research organization (CRO) that specializes in early-stage clinical drug research. Based...

    2020-12-01 8:30 AM ET
  • Entheon Biomedical to Begin Trading on the Frankfurt Exchange

    Vancouver, British Columbia--(Newsfile Corp. - November 26, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its shares have commenced trading on the Frankfurt Stock Exchange under the symbol "1XU1". The Frankfurt Stock Exchange is the world's tenth largest organized exchange-trading market in terms of turnover and dealings in securities. Over 3,000 international companies...

    2020-11-26 8:30 AM ET
  • Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange

    Vancouver, British Columbia--(Newsfile Corp. - November 12, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (formerly, MPV Exploration Inc.) ("Entheon" or the "Company") is pleased to announce that, further to its news release dated November 5, 2020, the Company has commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "ENBI". Timothy Ko, CEO of Entheon, stated: "We are thrilled by the opportunity that listing on the CSE presents. Addiction is a massive societal issue that can no longer...

    2020-11-12 8:30 AM ET
  • Entheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange

    Vancouver, British Columbia--(Newsfile Corp. - November 5, 2020) - Entheon Biomedical Corp. (CSE: MPV) (formerly, MPV Exploration Inc.) ("Entheon" or the "Company") is pleased to announce that further to its news releases dated July 2, 2020, September 10, 2020 and October 28, 2020, the Company has completed the previously announced business combination with Entheon Holdings Corp. (formerly, Entheon Biomedical Corp.) and has received final approval to list the Resulting Issuer Shares (as defined below) on the Canadian Securities Exchange...

    2020-11-05 7:59 PM ET
  • Entheon Biomedical Announces Private Placement to Begin Pre-clinical Trials with Psychedelic Compounds DMT & 5 MEO DMT

    Vancouver, British Columbia--(Newsfile Corp. - May 7, 2020) - Entheon Biomedical Corp. ("Entheon" or the "Company") announces that it intends to complete a private placement of up to 10,000,000 units (the "Units") at a price of $0.40 CDN per Unit for total gross proceeds of up to Cdn$4,000,000. Each Unit will consist of one common share and one-half of one warrant. Each whole warrant (a "Warrant") will entitle the holder to purchase one common share at a price of $0.60...

    2020-05-07 5:30 AM ET